摘要
本实验用流式细胞计对26名乳腺癌患者及14名正常对照者外周血T细胞亚群进行了检测,结果表明;(1)全组乳腺癌CD_3^+及CD_4^+细胞显著低于正常对照组,腋淋巴结移转组又明显低于腋淋巴结无转移组.(2)CD_8^+细胞随乳腺癌不同阶段呈特征性改变.(3)腋淋巴结转移组CD_4^+/CD_8^+比值明显低于正常对照及腋淋巴结无转移组.(4)CD_(16)^+细胞在正常对照及伴在不伴腋淋巴转移乳腺癌组之间无显著差异.上述结果提示:(1)机体对乳腺癌有相应的防御机能.(2)乳腺癌患者CD_(16)^+(LGL)细胞数与NK细胞活性无关且和正常对照组无异.(3)乳腺癌患者CD_3^+/CD_8^+比值可辅助评估伴腋淋巴转移乳腺癌患者的预后.
T cell subsets in peripheral blood were determined in 26 patients with breast cancer and 14 blood donors using FCM. It was shown that : 1. Percentages of CD3+ and CD4 + cells in this series of breast cancer were significantly lower than those in normal controls. Percentages of CD3+ and CD4 +cells in patients with metastatic axillary lymph nodes were significantly lower than those without axillary involvement. 2. Percentage of CD8+ cells characteristically changed with progress of breast cancer. 3. Value of CD4 + /CD8 + in patients with positive axilla was remarkably lower than those in normal controls and negative axilla patients. 4. There was no significant difference of CD16+ cells count between the normal controls and breast cancer patient disregarding metastatic status.The results indicate that ' 1. Human body has innate defending ability against breast cancer. 2. The number of CD16 + cells (LGL)in patients with breast cancer has no relation with the NK cells activity. NK cells activity of these patients bears no diversity with normal controls. 3. CD4 +/CDS + value in patients with breast cancer plays an auxiliary role in prognostic evaluation when combined with metastatic status of axillary lymph nodes.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
1994年第3期209-213,共5页
Chinese Journal of Clinical Oncology
